Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial – Authors’ reply

By sjmartinez • July 29, 2024

Rugo HS, Bardia A, Tolaney S. Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply. Lancet. 2024 Jul 27;404(10450):339-340. doi: 10.1016/S0140-6736(24)01049-3. PMID: 39067902.

Tags: Hematology/Oncology, Publications

Response to Zhang and Shi

Ji J, Cohen HJ, Sedrak MS. Response to Zhang and Shi. J Natl Cancer Inst. 2026 Oct 12:djag380. doi: 10.1093/jnci/djag380. Epub ahead of print. PMID:[...]

177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial

Kishan AU, Wilhalme H, Felix C, Enke J, Ali FZ, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom[...]

Author Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu[...]